

Application Serial No. 10/809,965

RECEIVED
CENTRAL FAX CENTER

PATENT
89212.0016

OCT 26 2006

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A method of detecting DNA markers in a sample, comprising:
providing a cell-free bone marrow sample from a subject; and
detecting one or more DNA markers in the sample.
2. (Original) The method of claim 1, wherein the DNA markers are in the 1p, 3p, 6p, 6q, 8p, 10q, 11q, 14q, 16q, or 17p region.
3. (Original) The method of claim 1, wherein the DNA markers are indicative of LOH, DNA hypermethylation, or DNA mutation.
4. (Original) The method of claim 1, wherein the DNA markers include D1S228, D8S321, D4S175, D4S1586, D5S299, D8S133, D8S261, D8S262, D8S264, D9S171, D10S197, D10S591, D10S532, D14S51, D14S62, D15S127, D16S421, D16S422, D17S796, D17S849, D17S855, D18S58, D18S61, or D18S70.
5. (Original) The method of claim 1, wherein the DNA markers are indicative of hypermethylation in RASSF1A, MGMT, GSTP1, RAR- β , TWIST, APC, DAPK, P16, or Cyclin D2 promoter.
6. (Original) The method of claim 1, wherein the DNA markers are indicative of mutation in KRAS or BRAF gene.
7. (Original) A method of detecting cancer, comprising

Application Serial No. 10/809,965

PATENT
89212.0016

providing a cell-free bone marrow sample from a subject; and
detecting one or more DNA markers in the sample, wherein LOH,
hypermethylation, or mutation of the markers is indicative of cancer in the subject.

8. (Original) The method of claim 7, wherein the cancer is melanoma,
neuroblastoma, colorectal, breast, or prostate cancer.

9. (Original) A method of staging cancer, comprising
providing a cell-free bone marrow sample from a subject suffering from
cancer; and

detecting one or more DNA markers in the sample, wherein LOH,
hypermethylation, or mutation of the markers is indicative of an advanced stage of
the cancer in the subject.

10. (Original) The method of claim 9, wherein the cancer is melanoma,
neuroblastoma, colorectal, breast, or prostate cancer.

11. (Original) A method of prognosing cancer, comprising
providing a cell-free bone marrow sample from a subject suffering from
cancer; and

detecting one or more DNA markers in the sample, wherein LOH,
hypermethylation, or mutation of the markers is indicative of a poor prognosis of
the cancer in the subject.

12. (Original) The method of claim 11, wherein the cancer is melanoma,
neuroblastoma, colorectal, breast, or prostate cancer.

13. (Original) A method of detecting LOH and DNA hypermethylation,
comprising

Application Serial No. 10/809,965

PATENT
89212.0016

providing a sample from a subject; and
detecting a combination of LOH and DNA hypermethylation in the sample.

14. (Original) The method of claim 13, wherein the sample is a serum, plasma or tissue sample.

15. (Original) The method of claim 13, wherein the LOH is indicated by one or more DNA markers that include D1S228, D8S321, D4S175, D4S1586, D5S299, D8S133, D8S261, D8S262, D8S264, D9S171, D10S197, D10S591, D10S532, D14S51, D14S62, D15S127, D16S421, D16S422, D17S796, D17S849, D17S855, D18S58, D18S61, or D18S70.

16. (Original) The method of claim 13, wherein the DNA hypermethylation is detected in RASSF1A, MGMT, GSTP1, RAR- β , TWIST, APC, DAPK, P16, KRAS, BRAF, or Cyclin D2 promoter.

17. (Original) A method of detecting cancer, comprising
providing a sample from a subject; and
detecting one or more DNA markers in the sample, wherein a combination of LOH and hypermethylation of the markers is indicative of cancer in the subject.

18. (Original) The method of claim 17, wherein the cancer is melanoma, neuroblastoma, colorectal, breast, or prostate cancer.

19. (Original) The method of claim 17, wherein the sample is a serum, plasma or tissue sample.

20. (Original) A method of staging cancer, comprising
providing a sample from a subject suffering from cancer; and

Application Serial No. 10/809,965

PATENT
89212.0016

detecting one or more DNA markers in the sample, wherein a combination of LOH and hypermethylation of the markers is indicative of an advanced stage of the cancer in the subject.

21. (Original) The method of claim 20, wherein the cancer is melanoma, neuroblastoma, colorectal, breast, or prostate cancer.

22. (Original) The method of claim 20, wherein the sample is a serum, plasma or tissue sample.

23. (Original) A method of prognosing cancer, comprising providing a sample from a subject suffering from cancer; and detecting one or more DNA markers in the sample, wherein a combination of LOH and hypermethylation of the markers is indicative of a poor prognosis of the cancer in the subject.

24. (Original) The method of claim 23, wherein the cancer is melanoma, neuroblastoma, colorectal, breast, or prostate cancer.

25. (Original) The method of claim 23, wherein the sample is a serum, plasma or tissue sample.

26. (Withdrawn) A packaged product, comprising a container; one or more agents for detecting one or more DNA markers in a sample; and an insert associated with the container and indicating that the sample is a cell-free bone marrow sample.

27. (Withdrawn) A packaged product, comprising

Application Serial No. 10/809,965

PATENT
89212.0016

a container;
one or more agents for detecting one or more DNA markers in a cell-free bone marrow sample from a subject; and
an insert associated with the container and indicating that LOH, hypermethylation, or mutation of the markers is indicative of cancer in the subject.

28. (Withdrawn) A packaged product, comprising
a container;
one or more agents for detecting one or more DNA markers in a cell-free bone marrow sample from a subject suffering from cancer; and
an insert associated with the container and indicating that LOH, hypermethylation, or mutation of the markers is indicative of an advanced stage of the cancer or a poor prognosis of the cancer in the subject.

29. (Withdrawn) A kit, comprising one or more agents for detecting a combination of LOH and DNA hypermethylation of one or more DNA markers in a sample.

30. (Withdrawn) A packaged product, comprising
a container;
one or more agents for detecting one or more DNA markers in a sample from a subject; and
an insert associated with the container and indicating that a combination of LOH and hypermethylation of the markers is indicative of cancer in the subject.

31. (Withdrawn) A packaged product, comprising
a container;
one or more agents for detecting one or more DNA markers in a sample from a subject suffering from cancer; and

Application Serial No. 10/809,965

PATENT
89212.0016

an insert associated with the container and indicating that a combination of LOH and hypermethylation of the markers is indicative of an advanced stage of the cancer or a poor prognosis of the cancer in the subject.